



# Southport and Formby Clinical Commissioning Group

Our ref: FOI ID 33175

30 January 2017

[southportandformbyccg.foi@nhs.net](mailto:southportandformbyccg.foi@nhs.net)

**NHS Southport & Formby CCG**

Merton House  
Stanley Road  
Bootle  
Merseyside  
L20 DL

Direct dial: 0151 247 7000

## Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding the usage of Infliximab services within NHS Southport and Formby CCG.

Request/[Response](#):

1. In the period of financial year to date:

- How many individual funding requests for the usage of Infliximab in the treatment of Hidradentis Suppurativa has the CCG received?

[NHS Southport and Formby CCG have received no funding requests for the usage of Infliximab.](#)

- Of the above, is it possible to say how may have been approved?

[Not applicable](#)

2. Are there any gainshare agreements in place between the CCG and a provider (e.g. hospital trust)?

If "Yes", then please provide the following details:

Disease area	Provider included in the gainshare agreement	Names of any specific drugs involved	What savings have been made (approximate amount)?

- [Yes there are gain-share agreements in place between NHS Southport and Formby CCG and the large acute providers, Aintree University Hospitals NHS Foundation](#)

Chair: Dr Rob Caudwell  
Chief Officer: Fiona Taylor

## ***Southport and Formby Clinical Commissioning Group***

Trust, Southport & Ormskirk Hospital NHS Trust and The Royal Liverpool and Broadgreen University Hospitals NHS Trust

- The gain-share agreements cover the transfer of patients over to biosimilar drugs, various disease areas and various drugs
- Gain share is only rolling out this year and savings are not yet quantifiable

3. Have any gainshare agreements been terminated, and if so which disease areas?

NHS Southport and Formby CCG are not aware of any gainshare agreements which have been terminated.